November 25, 2013

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Identifying targets of autoantibodies

Patients with the autoimmune disease systemic lupus erythematosus (SLE) produce autoantibodies that target can cause damage to multiple organ systems. The host factors that are targeted by autoantibodies produced by SLE patients are not fully understood.

In this issue of the Journal of Clinical Investigation, Jordan Price and colleagues at Stanford University developed a microarray to identify cytokines, chemokines, and other circulating proteins as potential targets of the autoantibodies produced by SLE patients. The authors identified several autoantibody targets, and determined that SLE patients with high levels of directed against the B cell activating factor (BAFF) had more severe SLE-associated symptoms.

In an accompanying commentary, Maureen Su of the University of North Carolina and Stephanie Sarantopoulos of Duke University discuss how identification of autoantibody targets produced by patients with will be informative for diagnosis and therapeutic strategy development.

More information: Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus, J Clin Invest. DOI: 10.1172/JCI70231
BAFF-ling autoantibodies, J Clin Invest. 2013;123(12):5006–5008. DOI: 10.1172/JCI73166

Journal information: Journal of Clinical Investigation

Load comments (0)